Entropy Technologies LP Grows Stake in Azenta, Inc. (NASDAQ:AZTA)

Entropy Technologies LP boosted its position in shares of Azenta, Inc. (NASDAQ:AZTA) by 19.1% during the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor owned 15,581 shares of the company’s stock after purchasing an additional 2,496 shares during the quarter. Entropy Technologies LP’s holdings in Azenta were worth $779,000 at the end of the most recent reporting period.

Several other large investors also recently bought and sold shares of the company. Sanctuary Advisors LLC purchased a new stake in shares of Azenta in the 2nd quarter worth about $222,000. Procyon Advisors LLC purchased a new stake in shares of Azenta in the third quarter valued at about $247,000. Wesbanco Bank Inc. grew its position in shares of Azenta by 72.2% in the third quarter. Wesbanco Bank Inc. now owns 31,000 shares of the company’s stock valued at $1,502,000 after purchasing an additional 13,000 shares during the last quarter. Net Worth Advisory Group acquired a new stake in Azenta during the 3rd quarter valued at $205,000. Finally, Allspring Global Investments Holdings LLC boosted its stake in shares of Azenta by 16.4% during the third quarter. Allspring Global Investments Holdings LLC now owns 1,298,856 shares of the company’s stock valued at $62,917,000 after acquiring an additional 183,040 shares during the last quarter. Institutional investors and hedge funds own 99.08% of the company’s stock.

Insider Transactions at Azenta

In other news, CFO Herman Cueto sold 712 shares of the stock in a transaction on Tuesday, November 19th. The shares were sold at an average price of $40.07, for a total value of $28,529.84. Following the completion of the sale, the chief financial officer now owns 23,892 shares of the company’s stock, valued at $957,352.44. This represents a 2.89 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, Director William L. Cornog bought 12,500 shares of the business’s stock in a transaction dated Monday, November 18th. The stock was acquired at an average cost of $39.60 per share, for a total transaction of $495,000.00. Following the purchase, the director now owns 14,755 shares in the company, valued at approximately $584,298. This trade represents a 554.32 % increase in their position. The disclosure for this purchase can be found here. Insiders have sold a total of 1,423 shares of company stock worth $57,020 in the last three months. 10.62% of the stock is currently owned by company insiders.

Analyst Upgrades and Downgrades

A number of equities analysts have recently weighed in on the stock. Needham & Company LLC boosted their price objective on shares of Azenta from $55.00 to $59.00 and gave the company a “buy” rating in a research report on Thursday, February 6th. Evercore ISI raised their price objective on Azenta from $50.00 to $52.00 and gave the stock an “in-line” rating in a report on Thursday, February 6th. Finally, Stephens reiterated an “overweight” rating and issued a $60.00 target price on shares of Azenta in a research note on Thursday, January 2nd.

Azenta Stock Performance

Shares of AZTA stock opened at $45.86 on Wednesday. The firm has a market capitalization of $2.10 billion, a price-to-earnings ratio of -15.39 and a beta of 1.47. Azenta, Inc. has a one year low of $38.82 and a one year high of $67.77. The company has a 50 day moving average price of $50.59 and a 200 day moving average price of $48.76.

Azenta (NASDAQ:AZTA) last released its quarterly earnings data on Wednesday, February 5th. The company reported $0.08 EPS for the quarter, topping analysts’ consensus estimates of $0.05 by $0.03. Azenta had a positive return on equity of 1.25% and a negative net margin of 24.91%. As a group, equities analysts forecast that Azenta, Inc. will post 0.42 EPS for the current fiscal year.

Azenta Profile

Azenta, Inc provides biological and chemical compound sample exploration and management solutions for the life sciences market in North America, Africa, China, the United Kingdom, rest of Europe, the Asia Pacific, and internationally. The company operates in two reportable segments, Life Sciences Products and Life Sciences Services.